MARKET

CADL

CADL

Candel Therapeutics, Inc.
NASDAQ
8.25
-0.41
-4.73%
Opening 15:50 03/25 EDT
OPEN
8.51
PREV CLOSE
8.66
HIGH
8.61
LOW
8.03
VOLUME
462.21K
TURNOVER
--
52 WEEK HIGH
14.60
52 WEEK LOW
1.450
MARKET CAP
389.69M
P/E (TTM)
-4.7359
1D
5D
1M
3M
1Y
5Y
1D
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
NASDAQ · 5h ago
Weekly Report: what happened at CADL last week (0317-0321)?
Weekly Report · 1d ago
Candel Therapeutics’ CAN-2409: Strategic Partnerships and Promising Clinical Data Drive Buy Rating
TipRanks · 4d ago
CANDEL THERAPEUTICS INC - PARTNERSHIP WITH IDEA PHARMA EXPECTED TO RUN THROUGH 2026
Reuters · 5d ago
CANDEL THERAPEUTICS AND IDEA PHARMA ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE PATH-TO-MARKET COMMERCIALIZATION EFFORTS FOR CAN-2409
Reuters · 5d ago
Weekly Report: what happened at CADL last week (0310-0314)?
Weekly Report · 03/17 11:56
Candel Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 16:29
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target
Benzinga · 03/14 16:20
More
About CADL
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Webull offers Candel Therapeutics Inc stock information, including NASDAQ: CADL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CADL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CADL stock methods without spending real money on the virtual paper trading platform.